Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by jimsenioron Oct 19, 2022 12:41pm
155 Views
Post# 35033966

RE:Companies now seek to moderate TME to expand PD-(L)1 effect

RE:Companies now seek to moderate TME to expand PD-(L)1 effect
A  very interesting article admtting that PD-1/PD-L1 is not enough.
CD8 is mentioned on slide 25 of the current presentation, and also in Preinduced reovirus-specific T-cell immunity enhances the anticancer efficacy of reovirus, and elsewhere I am sure. I do not really know what it means, and have come to the conclusion that this whole subject is too complex for most. Conclusion: this is so complex, we shall have to wait for a news release that explains clearly and definitively what is going on, and that is not something it seems that is easy to  present. GLTA.

Sill very positive from a layman's perspective, but this may take more time.
<< Previous
Bullboard Posts
Next >>